-transparent.png){kind=logo}
Nine hospitalized schizophrenic patients with tardive dyskinesia were treated with the calcium-channel antagonist verapamil under single-blind conditions. The tardive dyskinesia and activation scores decreased, and the anxiety/depression scores increased. The changes were small but statistically significant.
Related Publications
S Reiter, and
L Adler, and
B Angrist, and
E Peselow, and
J Rotrosen
February 1991,
Journal of clinical psychopharmacology,
S Reiter, and
L Adler, and
B Angrist, and
E Peselow, and
J Rotrosen
January 1986,
Psychopharmacology bulletin,
S Reiter, and
L Adler, and
B Angrist, and
E Peselow, and
J Rotrosen
May 1981,
The American journal of psychiatry,
S Reiter, and
L Adler, and
B Angrist, and
E Peselow, and
J Rotrosen
June 2011,
Journal of psychopharmacology (Oxford, England),
S Reiter, and
L Adler, and
B Angrist, and
E Peselow, and
J Rotrosen
January 2003,
Pharmacopsychiatry,
S Reiter, and
L Adler, and
B Angrist, and
E Peselow, and
J Rotrosen
January 1985,
Annals of the Academy of Medicine, Singapore,
S Reiter, and
L Adler, and
B Angrist, and
E Peselow, and
J Rotrosen
January 1998,
European archives of psychiatry and clinical neuroscience,
S Reiter, and
L Adler, and
B Angrist, and
E Peselow, and
J Rotrosen
October 1994,
Psychiatry research,
S Reiter, and
L Adler, and
B Angrist, and
E Peselow, and
J Rotrosen
January 1988,
Biological psychiatry,
S Reiter, and
L Adler, and
B Angrist, and
E Peselow, and
J Rotrosen
August 1989,
Archives of general psychiatry,
